BACKGROUND: The Bionas 2500(®) analyzing system is an advanced label-free technology using a cell-based multi-sensor array, which is commercially available. Data on metabolism, respiration, adhesion, cell proliferation and cell death rates, as well as ligand-receptor interactions (multi-parametric) can be acquired and statistically evaluated. Noteworthy is the possibility of analyzing later after effects and/or recovery after drug treatment. In addition, Bionas supports all conceivable drug application modes (one, two or more drugs). Specimens for drug screening with Bionas consist of human permanent cell lines, primary cell cultures as well as 'tumor slices' obtained from biopsies and surgery material. OBJECTIVE/METHODS: Examples of measurements are presented and discussed. CONCLUSION: Although drug throughput is modest, the high quality of the information allows in-depth evaluation.
No takes yet. Share an insight, caveat, or question.
Mestres et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: